Youngbo Chemical Past Earnings Performance
Past criteria checks 2/6
Youngbo Chemical has been growing earnings at an average annual rate of 3.4%, while the Chemicals industry saw earnings growing at 12.4% annually. Revenues have been declining at an average rate of 13.1% per year. Youngbo Chemical's return on equity is 3.7%, and it has net margins of 6.7%.
Key information
3.4%
Earnings growth rate
3.4%
EPS growth rate
| Chemicals Industry Growth | 13.9% |
| Revenue growth rate | -13.1% |
| Return on equity | 3.7% |
| Net Margin | 6.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Are Dividend Investors Getting More Than They Bargained For With Youngbo Chemical Co., Ltd.'s (KRX:014440) Dividend?
Apr 30
Here's Why Youngbo Chemical (KRX:014440) Can Manage Its Debt Responsibly
Mar 01Youngbo Chemical Co., Ltd. (KRX:014440) Investors Should Think About This Before Buying It For Its Dividend
Jan 23Reflecting on Youngbo Chemical's (KRX:014440) Share Price Returns Over The Last Three Years
Dec 27
Does Youngbo Chemical (KRX:014440) Have A Healthy Balance Sheet?
Dec 01Revenue & Expenses BreakdownBeta
How Youngbo Chemical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 90,279 | 6,079 | 12,589 | 1,975 |
| 30 Sep 23 | 88,365 | 5,794 | 12,908 | 2,235 |
| 30 Jun 23 | 87,412 | 7,242 | 11,864 | 2,147 |
| 31 Mar 23 | 85,356 | 6,755 | 11,270 | 2,039 |
| 31 Dec 22 | 82,989 | 7,081 | 11,111 | 1,951 |
| 30 Sep 22 | 78,428 | 4,603 | 10,805 | 1,865 |
| 30 Jun 22 | 75,155 | 3,962 | 11,201 | 1,823 |
| 31 Mar 22 | 68,771 | 3,320 | 10,554 | 1,784 |
| 31 Dec 21 | 76,803 | 2,344 | 12,216 | 1,903 |
| 30 Sep 21 | 87,449 | 3,095 | 13,663 | 1,622 |
| 30 Jun 21 | 97,737 | 3,564 | 15,042 | 1,490 |
| 31 Mar 21 | 108,912 | 2,866 | 16,964 | 1,367 |
| 31 Dec 20 | 107,369 | 2,842 | 16,389 | 1,344 |
| 30 Sep 20 | 108,095 | 2,002 | 16,464 | 1,649 |
| 30 Jun 20 | 109,044 | 746 | 16,873 | 1,974 |
| 31 Mar 20 | 122,450 | 3,030 | 18,321 | 2,226 |
| 31 Dec 19 | 131,196 | 5,120 | 19,006 | 2,103 |
| 30 Sep 19 | 132,823 | 5,932 | 20,314 | 1,927 |
| 30 Jun 19 | 139,663 | 7,298 | 20,116 | 1,914 |
| 31 Mar 19 | 140,481 | 7,381 | 19,526 | 2,090 |
| 31 Dec 18 | 143,915 | 5,733 | 20,894 | 2,387 |
| 30 Sep 18 | 151,077 | 5,358 | 20,000 | 2,603 |
| 30 Jun 18 | 157,692 | 7,199 | 20,486 | 2,531 |
| 31 Mar 18 | 160,909 | 28,599 | 20,237 | 2,363 |
| 31 Dec 17 | 164,618 | 29,288 | 19,849 | 2,262 |
| 30 Sep 17 | 168,686 | 31,355 | 20,435 | 2,234 |
| 30 Jun 17 | 163,910 | 29,800 | 19,866 | 2,259 |
| 31 Mar 17 | 162,305 | 9,984 | 20,324 | 2,243 |
| 31 Dec 16 | 157,804 | 10,909 | 19,491 | 2,139 |
| 30 Sep 16 | 151,013 | 6,994 | 20,686 | 2,159 |
| 30 Jun 16 | 153,258 | 8,392 | 21,328 | 2,027 |
| 31 Mar 16 | 152,915 | 6,916 | 21,102 | 1,881 |
| 31 Dec 15 | 157,352 | 9,127 | 21,668 | 1,795 |
| 30 Sep 15 | 158,990 | 8,988 | 21,376 | 1,587 |
| 30 Jun 15 | 156,102 | 7,048 | 20,442 | 1,464 |
| 31 Mar 15 | 158,420 | 7,762 | 20,215 | 1,370 |
| 31 Dec 14 | 157,432 | 3,688 | 20,705 | 1,413 |
| 30 Sep 14 | 161,283 | 5,941 | 19,337 | 1,437 |
| 30 Jun 14 | 166,619 | 6,445 | 21,078 | 1,483 |
| 31 Mar 14 | 168,297 | 7,045 | 21,755 | 1,622 |
| 31 Dec 13 | 163,839 | 8,430 | 20,375 | 1,478 |
| 30 Sep 13 | 158,440 | 7,249 | 20,858 | 1,452 |
| 30 Jun 13 | 149,647 | 6,584 | 18,854 | 1,400 |
Quality Earnings: A014440 has high quality earnings.
Growing Profit Margin: A014440's current net profit margins (6.7%) are lower than last year (8.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A014440's earnings have grown by 3.4% per year over the past 5 years.
Accelerating Growth: A014440's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A014440 had negative earnings growth (-14.1%) over the past year, making it difficult to compare to the Chemicals industry average (-15.5%).
Return on Equity
High ROE: A014440's Return on Equity (3.7%) is considered low.